Clinical trials: Heptocellular Cancer
Heptocellular Cancer
Radioembolization Versus External Radiation Therapy
The proposed study is a single site, prospective, randomized phase 2 study to evaluate the efficacy and tolerability transarterial radioembolization (TARE) versus stereotactic body radiation therapy (SBRT) for hepatocellular…
- Trial name
- REVERT (NCT07530172)
- Testing
- Transarterial Radioembolization, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Henry Ford Health System
Liver Cancer
Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer
In this study, effects of γδT cells on human hepatocellular liver cancer in combination with tumor reducing surgery, for example cryosurgery going to be investigated.
- Trial name
- NCT02425735
- Testing
- DC-CIK cells, γδ T cells, γδ T/DC-CIK cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Heptocellular Cancer, Biliary Tract Neoplasms
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Background: Tremelimumab is a cancer treatment drug that helps the immune system recognize and destroy cancer cells. Researchers want to see if it can be used to treat advanced liver cancer.
- Conditions
- Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- NCT01853618
- Testing
- Tremelimumab, RFA, TACE
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
HCC, Hepatocellular Carcinoma
Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study
Non-invasive MRI subclassification of Heptocellular Carcinoma - HepCaSt-Study
- Conditions
- HCC, Hepatocellular Carcinoma, MRI
- Trial name
- HepCaSt (NCT05202015)
- Testing
- MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Charite University, Berlin, Germany